<DOC>
	<DOCNO>NCT00706667</DOCNO>
	<brief_summary>Study Design : Single-centre , block randomise , blind , control , phase IIIb , parallel group pilot study . Primary Objective : • To evaluate effect administration ferric carboxymaltose ( Ferinject® ) without erythropoietin vs. treatment ( standard therapy ) preoperative anaemia status patient undergo orthopaedic surgery Secondary Objective : - To gain information design possible follow-up study - To evaluate effect administration ferric carboxymaltose ( Ferinject® ) without erythropoietin vs. treatment ( standard therapy ) pre- postoperative Hb level , iron status , transfusion rate , day discharge . - To evaluate tolerability safety Ferinject® Study Centres : This single centre study Patients : A total 75 complete patient ( 50 patient intravenous iron treatment group 25 patient treatment group recruit .</brief_summary>
	<brief_title>Intravenous Ferric Carboxymaltose ( Ferinject® ) With Without Erythropoietin Patients Undergoing Orthopaedic Surgery</brief_title>
	<detailed_description>TREATMENT : Patients randomise 1:1:1 one follow group : Group I - Ferinject ® EPO treatment group 25 patient randomised Ferinject EPO treatment group . For patient , cumulative total iron requirement calculate use formula Ganzoni [ Ganzoni et al , 1970 ] : Iron deficit [ mg ] = b.w . [ kg ] † x ( target Hb - actual Hb ) [ g/L ] x 0.24†† + depot iron [ mg ] † In patient body mass index ( BMI = weight [ kg ] / ( height [ ] x height [ ] ) ) &gt; 25 , normalise weight use calculate iron deficit . Normalised weight [ kg ] = 25 x height [ ] x height [ ] . †† Factor 0.24 = 0.0034 ( iron content Hb = 0.34 % ) * 0.07 ( blood volume = 7 % b.w . ) * 1000 ( conversion g mg ) Target Hb : 150 g/L Actual Hb : Value obtain screen visit Depot iron : 500 mg Patients receive first dose 1000 mg iron Ferinject® 21 day prior schedule surgery . Patients receive Ferinject® weekly two occasion ( Day -21 Day -14 ) calculate cumulative dose reach individual . The Day -14 infusion may necessary , depend calculate total iron requirement patient . Patients treatment group 1 get additionally single 10000 IU dose EPO together treatment day -14 . Group II - Ferinject ® treatment group 25 patient randomised Ferinject without EPO . For patient , cumulative total iron requirement calculate use formula Ganzoni [ Ganzoni et al , 1970 ] : Iron deficit [ mg ] = b.w . [ kg ] † x ( target Hb - actual Hb ) [ g/L ] x 0.24†† + depot iron [ mg ] † In patient body mass index ( BMI = weight [ kg ] / ( height [ ] x height [ ] ) ) &gt; 25 , normalise weight use calculate iron deficit . Normalised weight [ kg ] = 25 x height [ ] x height [ ] . †† Factor 0.24 = 0.0034 ( iron content Hb = 0.34 % ) * 0.07 ( blood volume = 7 % b.w . ) *1000 ( conversion g mg ) Target Hb : 150 g/L Actual Hb : Value obtain screen visit Depot iron : 500 mg Patients receive first dose 1000 mg iron Ferinject 21 day prior schedule surgery . Patients receive Ferinject® weekly two occasion ( Day -21 Day -14 ) calculate cumulative dose reach individual . The Day -14 infusion may necessary , depend calculate total iron requirement patient . Group III - Control group 25 patient receive standard treatment patient population ( anaemia treatment ) . Primary Efficacy Endpoints • Hb increase baseline till day surgery Secondary Efficacy Endpoints - Percentage patient reach Hb &gt; 12 g/dl ( woman ) &gt; 13 g/dl ( men ) point time study - Change Hb level baseline high Hb level study - Change Ferritin value baseline high ferritin value study - Change Tsat value baseline high Tsat value study - Transfusion rate - Infection rate - Days discharge hospital - Days rehabilitation therapy Secondary Safety Endpoints : - Adverse event : type , nature , incidence outcome - Vital sign ( temperature , blood pressure heart rate ) - Clinical laboratory panel ( haematology/coagulation , clinical chemistry , except Hb iron status , consider efficacy endpoint ) Laboratory parameter : Hematology/coagulation parameter analyse Hb , haematocrit ( Hct ) , red blood cell count ( RBC ) , white blood cell count ( WBC ) differential platelet count , mean corpuscular volume ( MCV ) , mean corpuscular haemoglobin ( MCH ) , mean corpuscular haemoglobin concentration ( MCHC ) . Clinical chemistry parameter analyse alkaline phosphatase ( AP ) , gamma-glutamyl transpeptidase ( GGT ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , C-reactive protein ( CRP ) , endogenous erythropoietin . Iron status parameter include serum iron , serum ferritin , serum transferrin TSAT . Additional parameter - folic acid , vitamin B12 beta-HCG analyse baseline , creatinin , soluble transferrin receptor total bilirubin analyse visit . Statistical Methods : Summary statistic provide safety efficacy parameter well patient ' demographic characteristic . Data present per visit , appropriate . The test primary endpoint confirmative . Statistical test secondary endpoint employ exploratory purpose highlight interesting comparison ( e.g. , baseline versus end study ) may warrant consideration . Unless otherwise specify , significance level statistical test 5 % two-sided alternative . If appropriate , correspond 95 % -confidence interval calculate . The sample size estimation base t-test calculation . Continuous variable summarize mean +/- SD median range appropriate . Continuous variable compare use Kruskal-Wallis test follow pairwise Mann-Whitney test Bonferroni-correction . Nominal variable compare use chi-square test Fisher 's exact test appropriate . Changes within group nominal variable analyze use McNemar test . Changes within group continuous variable analyze use Friedman test follow pairwise post hoc comparison use Wilcoxon sign rank test Bonferroni correction . Prevalence anaemia present exact confidence interval ( CI ) . Continuous variable transform normal distribution , CIs mean compute . The limit CIs retransformed original unit interpret CIs median .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>&gt; 18 year age sign write informed consent Patients schedule undergo major orthopaedic surgery ( hip knee arthroplasty back surgery ) 10 g/dl &lt; Hb &lt; 13.0 g/dl men 10 g/dl &lt; Hb &lt; 12.0 g/dl woman , screen ( 3 week prior surgery ) Ferritin &lt; 100 μg/l 100300 TSat &lt; 20 % Suspicion iron overload ( Ferritin &gt; 300 μg/l or/and TSAT &gt; 50 % ) Active severe infection/inflammation ( define serum CRP &gt; 20 mg/l ) diagnose malignancy Folateand/or Vitamin B12 deficiency ( accord local lab reference range ) Known history hepatitis B/C HIVpositive Liver value 3 time higher normal Immunosuppressive myelosuppressive therapy A concurrent medical condition ( ) , view investigator , would prevent compliance participation jeopardize health patient . Pregnancy lactation Transfusion within 1 month prior study inclusion , EPO treatment last 4 week , iron treatment within 4 week prior inclusion trail Participation therapeutic trial within previous month History thromboembolic event family patient Severe peripheral , coronary carotid artery disease Bodyweight &lt; 50 kg Patients able understand German language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>